Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ImmunD is a pharmaceutical brand of cholecalciferol (Vitamin D3), a fat-soluble secosteroid essential for maintaining calcium and phosphate homeostasis. It is primarily indicated for the treatment and prevention of Vitamin D deficiency, osteoporosis, and related bone disorders. Cholecalciferol acts as a prohormone that is metabolically converted to its active form, calcitriol (1,25-dihydroxyvitamin D3), through sequential hydroxylations in the liver and kidneys. Calcitriol functions as a high-affinity ligand for the Vitamin D Receptor (VDR), a nuclear transcription factor. Upon activation, the VDR-calcitriol complex modulates the expression of genes involved in intestinal calcium absorption, renal calcium handling, and bone remodeling. Additionally, ImmunD plays a significant role in immune modulation by enhancing the antimicrobial activities of innate immune cells and regulating adaptive immune responses.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ImmunD.